-
UPDATE: BMO Capital Starts Incyte (INCY) at Market Perform
-
Olumiant 2mg FDA Approval is Incrementally Negative for AbbVie (ABBV) - BMO
-
Bari Adcom Negative for Eli Lilly (LLY) and AbbVie (ABBV), Positive for Pfizer (PFE) - BMO
-
Incyte (INCY) PT Raised to $175 at BMO Capital; 'We Like Risk/Reward Heading into ECHO-301'
-
Incyte (INCY): Thoughts From BMS-986205 Trial Data - BMO
-
Incyte (INCY) PT Raised to $166 at BMO Capital, Street High
-
Incyte (INCY): Cutting PT Despite Positive Data From ESMO - BMO
-
ECHO-202 Adds to Incyte (INCY) Momentum - BMO Capital
-
FDA Pull Forward on Baricitinib Positive for Incyte (INCY), BMO Capital Says
-
Incyte (INCY): Handicapping ESMO - BMO
-
Buy Incyte (INCY) on Weakness - BMO Capital
-
Incyte (INCY): Raising PT To $166 On ASCO Presentation - BMO
-
Incyte (INCY): May 17th To Be A Positive Catalyst - BMO
-
Incyte (INCY) PT Raised to $146 at BMO Capital
-
Incyte (INCY) PT Lowered to $144 at BMO Capital
-
BMO Capital Reiterates Outpeform Rating and $170 PT on Incyte (INCY) Following BMS Agreement; 'Epacadostat is Real Deal'
-
Incyte (INCY) PT Raised to $170 at BMO Capital; 'Merck Deal Secures Leadership Position in IDO Race'
-
Incyte (INCY): Raising PT On Additional Sources of Upside - BMO
-
Incyte (INCY): Raising PT On Extension Of epacadostat - BMO Capital
-
Incyte (INCY) Meeting Highlights Upside in Jakafi and Pipeline - BMO
-
Incyte (INCY) PT Lifted to $126 at BMO Capital Following Competitor Set-Back
-
Today's Biotech Upside Could Be Just the Start - BMO Capital (IBB) (XBI)
-
Streetinsider.com's Hot Lunchtime Reads 10/7: (BA) (INCY) (CLVS) (DB)
-
Incyte (INCY) PT Raised to $121 at BMO Capital on Higher Probability of Epacadostat+Keytruda Sucecss
-
Incyte Corp (INCY): Raising PT After Management Meeting - BMO
-
BMO Capital Starts Incyte (INCY) at Outperform
-
Notable Analyst Rating Changes 02/26: (LNKD) (RRC) (ARIA) Upgraded; (PSA) (NIHD) (HUM) Downgraded
-
Notable Analyst Rating Changes 01/10: (MSFT) (INCY) (TGT) Upgraded; (LLY) (AMBA) (CUDA) Downgraded
-
Notable Analyst Rating Changes 12/05: (TLEO) (EBAY) (HMA) Upgraded; (CVC) (ADSK) (SCS) Downgraded
-
BMO Capital Starts Incyte (INCY) at Market Perform